• Research and Development

  AD-114 for IPF Reduces Disease Progression in Patient-derived Cells and Mice

  Posted by Pulmonary Fibrosis News Moderator on April 6, 2018 at 6:45 pm

  An Australian study showed that AD-114, an investigative therapy for idiopathic pulmonary fibrosis (IPF) developed by AdAlta, prevented the infiltration of immune cells and collagen build-up in lung cells from IPF patients. AD-114 also reduced fibrotic injury in a mouse model.

  The study, “Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis,” was published in the journal Scientific Reports.

  Read more about this study here: “AD-114 for IPF Reduces Disease Progression in Patient-derived Cells and Mice, Study Shows“

  What do you think about this study? Please share your thoughts below.

  Pulmonary Fibrosis News Moderator replied 6 years ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply